These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25241975)

  • 1. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
    Li H; Li X; Xie F
    Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis).
    Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
    Trans Am Ophthalmol Soc; 2013 Sep; 111():56-69. PubMed ID: 24167325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
    Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA; Wordsworth S; Rogers CA; Abangma G; Raftery J; Harding SP; Lotery AJ; Downes SM; Chakravarthy U; Reeves BC;
    BMJ Open; 2014 Jul; 4(7):e005094. PubMed ID: 25079928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity.
    Butt T; Patel PJ; Tufail A; Rubin GS
    Appl Health Econ Health Policy; 2014 Jun; 12(3):289-97. PubMed ID: 24610632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
    Elshout M; van der Reis MI; Webers CA; Schouten JS
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
    Athanasakis K; Fragoulakis V; Tsiantou V; Masaoutis P; Maniadakis N; Kyriopoulos J
    Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.
    Raftery J; Clegg A; Jones J; Tan SC; Lotery A
    Br J Ophthalmol; 2007 Sep; 91(9):1244-6. PubMed ID: 17431015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
    Stein JD; Newman-Casey PA; Kim DD; Nwanyanwu KH; Johnson MW; Hutton DW
    Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.
    Butt T; Lee A; Lee C; Tufail A;
    BMJ Open; 2015 May; 5(5):e006535. PubMed ID: 25943370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
    Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
    Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV
    Ophthalmology; 2013 May; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.